AstraZeneca’s antibody therapy prevents COVID-19 in study
FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo
AstraZeneca said on Friday its antibody therapy met the main goal of preventing COVID-19 disease in a late-stage study, putting the British drugmaker on track to potentially offer an alternative to vaccines for people with weakened immune systems.
The company said the cocktail of two types of antibodies, initially discovered by Vanderbilt University Medical Center, reduced by 77% the risk of developing symptomatic COVID-19, the potentially deadly disease caused by the coronavirus.
ADVERTISEMENT
More than 75% of the participants had chronic conditions, including some linked to a diminished immune response to vaccination, it said.
The results mark a change of fortune for the drugmaker, which reported in June that a smaller late-stage trial failed to provide evidence that the antibody cocktail, known for now as AZD7442, protected people who had contact with an infected person from the disease.
The Anglo-Swedish drugmaker, which has faced challenges with the rollout of its COVID-19 vaccine, is also working on repurposing existing drugs to fight the virus.
Subscribe to our daily newsletter
For more news about the novel coronavirus click
here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this
link
.
Read Next
On FPJ’s 82nd birthday, Poe recalls ‘Da King’s’ ‘unwavering spirit’ to aid poor and helpless
EDITORS’ PICK
MOST READ
Don’t miss out on the latest news and information.
View comments